Loading…

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK mo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacokinetics and pharmacodynamics 2001-12, Vol.28 (6), p.507-532
Main Authors: MAGER, Donald E, JUSKO, William J
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c422t-6da2d8c92934348a83a7e95d053d7c67c5ebd5e9e3938cef246a92471b2e12c03
cites
container_end_page 532
container_issue 6
container_start_page 507
container_title Journal of pharmacokinetics and pharmacodynamics
container_volume 28
creator MAGER, Donald E
JUSKO, William J
description Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.
doi_str_mv 10.1023/a:1014414520282
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71316403</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2157705481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-6da2d8c92934348a83a7e95d053d7c67c5ebd5e9e3938cef246a92471b2e12c03</originalsourceid><addsrcrecordid>eNpd0E1LxDAQBuAgiruunr1JEfRWzVeT1pssugoLHlTwVtJkupu1bWrSgv57o64IHoaZw8PwziB0TPAFwZRdqiuCCeeEZxTTnO6gKckkS3PJ-e7XLGQa62WCDkLYYExEdPtoQkhRFLTAU_S4gA68apJ-rXyrtHu1HQxWJ60z0CS184nx4yok8L62lR1st0oG5VcwpC0YqwYw3yAxNvQuROC6Q7RXqybA0bbP0PPtzdP8Ll0-LO7n18tUc0qHVBhFTa5jDsYZz1XOlIQiMzhjRmohdQaVyaAAVrBcQ025UAXlklQUCNWYzdD5z97eu7cRwlC2NmhoGtWBG0MpCSOCYxbh6T-4caPvYrZSZhIzKQmJ6GSLxiqeVvbetsp_lL-_iuBsC1TQqqm96rQNf44JKlies0_ShHha</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>757037711</pqid></control><display><type>article</type><title>General pharmacokinetic model for drugs exhibiting target-mediated drug disposition</title><source>Springer Nature</source><creator>MAGER, Donald E ; JUSKO, William J</creator><creatorcontrib>MAGER, Donald E ; JUSKO, William J</creatorcontrib><description>Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.</description><identifier>ISSN: 1567-567X</identifier><identifier>EISSN: 1573-8744</identifier><identifier>DOI: 10.1023/a:1014414520282</identifier><identifier>PMID: 11999290</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Biological and medical sciences ; Dose-Response Relationship, Drug ; Drug Delivery Systems - methods ; Drug Delivery Systems - statistics &amp; numerical data ; Drug Evaluation, Preclinical - methods ; Drug Evaluation, Preclinical - statistics &amp; numerical data ; Drug therapy ; Fluorenes - blood ; Fluorenes - pharmacokinetics ; General pharmacology ; Humans ; Hydantoins - blood ; Hydantoins - pharmacokinetics ; Interferon-beta - blood ; Interferon-beta - pharmacokinetics ; Male ; Medical sciences ; Models, Chemical ; Nonlinear Dynamics ; Pharmacokinetics ; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions ; Pharmacology. Drug treatments ; Sulfonamides - blood ; Sulfonamides - pharmacokinetics</subject><ispartof>Journal of pharmacokinetics and pharmacodynamics, 2001-12, Vol.28 (6), p.507-532</ispartof><rights>2002 INIST-CNRS</rights><rights>Plenum Publishing Corporation 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-6da2d8c92934348a83a7e95d053d7c67c5ebd5e9e3938cef246a92471b2e12c03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13626388$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11999290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MAGER, Donald E</creatorcontrib><creatorcontrib>JUSKO, William J</creatorcontrib><title>General pharmacokinetic model for drugs exhibiting target-mediated drug disposition</title><title>Journal of pharmacokinetics and pharmacodynamics</title><addtitle>J Pharmacokinet Pharmacodyn</addtitle><description>Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.</description><subject>Biological and medical sciences</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Delivery Systems - statistics &amp; numerical data</subject><subject>Drug Evaluation, Preclinical - methods</subject><subject>Drug Evaluation, Preclinical - statistics &amp; numerical data</subject><subject>Drug therapy</subject><subject>Fluorenes - blood</subject><subject>Fluorenes - pharmacokinetics</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Hydantoins - blood</subject><subject>Hydantoins - pharmacokinetics</subject><subject>Interferon-beta - blood</subject><subject>Interferon-beta - pharmacokinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Models, Chemical</subject><subject>Nonlinear Dynamics</subject><subject>Pharmacokinetics</subject><subject>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</subject><subject>Pharmacology. Drug treatments</subject><subject>Sulfonamides - blood</subject><subject>Sulfonamides - pharmacokinetics</subject><issn>1567-567X</issn><issn>1573-8744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNpd0E1LxDAQBuAgiruunr1JEfRWzVeT1pssugoLHlTwVtJkupu1bWrSgv57o64IHoaZw8PwziB0TPAFwZRdqiuCCeeEZxTTnO6gKckkS3PJ-e7XLGQa62WCDkLYYExEdPtoQkhRFLTAU_S4gA68apJ-rXyrtHu1HQxWJ60z0CS184nx4yok8L62lR1st0oG5VcwpC0YqwYw3yAxNvQuROC6Q7RXqybA0bbP0PPtzdP8Ll0-LO7n18tUc0qHVBhFTa5jDsYZz1XOlIQiMzhjRmohdQaVyaAAVrBcQ025UAXlklQUCNWYzdD5z97eu7cRwlC2NmhoGtWBG0MpCSOCYxbh6T-4caPvYrZSZhIzKQmJ6GSLxiqeVvbetsp_lL-_iuBsC1TQqqm96rQNf44JKlies0_ShHha</recordid><startdate>20011201</startdate><enddate>20011201</enddate><creator>MAGER, Donald E</creator><creator>JUSKO, William J</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20011201</creationdate><title>General pharmacokinetic model for drugs exhibiting target-mediated drug disposition</title><author>MAGER, Donald E ; JUSKO, William J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-6da2d8c92934348a83a7e95d053d7c67c5ebd5e9e3938cef246a92471b2e12c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Biological and medical sciences</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Delivery Systems - statistics &amp; numerical data</topic><topic>Drug Evaluation, Preclinical - methods</topic><topic>Drug Evaluation, Preclinical - statistics &amp; numerical data</topic><topic>Drug therapy</topic><topic>Fluorenes - blood</topic><topic>Fluorenes - pharmacokinetics</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Hydantoins - blood</topic><topic>Hydantoins - pharmacokinetics</topic><topic>Interferon-beta - blood</topic><topic>Interferon-beta - pharmacokinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Models, Chemical</topic><topic>Nonlinear Dynamics</topic><topic>Pharmacokinetics</topic><topic>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</topic><topic>Pharmacology. Drug treatments</topic><topic>Sulfonamides - blood</topic><topic>Sulfonamides - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MAGER, Donald E</creatorcontrib><creatorcontrib>JUSKO, William J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MAGER, Donald E</au><au>JUSKO, William J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>General pharmacokinetic model for drugs exhibiting target-mediated drug disposition</atitle><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle><addtitle>J Pharmacokinet Pharmacodyn</addtitle><date>2001-12-01</date><risdate>2001</risdate><volume>28</volume><issue>6</issue><spage>507</spage><epage>532</epage><pages>507-532</pages><issn>1567-567X</issn><eissn>1573-8744</eissn><abstract>Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>11999290</pmid><doi>10.1023/a:1014414520282</doi><tpages>26</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1567-567X
ispartof Journal of pharmacokinetics and pharmacodynamics, 2001-12, Vol.28 (6), p.507-532
issn 1567-567X
1573-8744
language eng
recordid cdi_proquest_miscellaneous_71316403
source Springer Nature
subjects Biological and medical sciences
Dose-Response Relationship, Drug
Drug Delivery Systems - methods
Drug Delivery Systems - statistics & numerical data
Drug Evaluation, Preclinical - methods
Drug Evaluation, Preclinical - statistics & numerical data
Drug therapy
Fluorenes - blood
Fluorenes - pharmacokinetics
General pharmacology
Humans
Hydantoins - blood
Hydantoins - pharmacokinetics
Interferon-beta - blood
Interferon-beta - pharmacokinetics
Male
Medical sciences
Models, Chemical
Nonlinear Dynamics
Pharmacokinetics
Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions
Pharmacology. Drug treatments
Sulfonamides - blood
Sulfonamides - pharmacokinetics
title General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T02%3A52%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=General%20pharmacokinetic%20model%20for%20drugs%20exhibiting%20target-mediated%20drug%20disposition&rft.jtitle=Journal%20of%20pharmacokinetics%20and%20pharmacodynamics&rft.au=MAGER,%20Donald%20E&rft.date=2001-12-01&rft.volume=28&rft.issue=6&rft.spage=507&rft.epage=532&rft.pages=507-532&rft.issn=1567-567X&rft.eissn=1573-8744&rft_id=info:doi/10.1023/a:1014414520282&rft_dat=%3Cproquest_pubme%3E2157705481%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c422t-6da2d8c92934348a83a7e95d053d7c67c5ebd5e9e3938cef246a92471b2e12c03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=757037711&rft_id=info:pmid/11999290&rfr_iscdi=true